ALFA FinderNSE filing, NSE: NATCOPHARM. Summary written from the filing by ALFA Finder's alert engine.
Natco Pharma Ltd: key numbers
- Share price
- ₹807.00
- Market cap
- ₹15,831 Cr
- Revenue (annual)
- ₹4,078 Cr
- Net profit (annual)
- ₹1,418 Cr
- P/E (TTM)
- 13.8×Sector 43.0×
- Promoter holding
- 46.22%-3.20% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natco Pharma Ltd
All →Natco Pharma Share Pledge
Natco Pharma promoter V.C. Nannapaneni pledged 8,50,000 equity shares to Bajaj Financial Securities Limited. The pledge supports the promoter's subscription to the company's Rights Issue.
Natco Pharma Other Announcement
Natco Pharma filed its shareholding pattern with a reporting date of 23 October 2026. Promoter and promoter group hold about 46% of total equity.
Natco Pharma Capital Structure Change
Natco Pharma allotted 5,86,666 equity shares to promoter Venkaiah Chowdary Nannapaneni via its rights issue, valued at ~₹44 Crore. This lifts his stake to 14.60%.
- Value
- ₹44.00 Cr
Natco Pharma Employee Stock Options
Natco Pharma's insiders, including promoters and directors, were allotted equity shares. This allotment increases their total shareholding in the company.
- Value
- ₹144.2 Cr
Natco Pharma Board Meeting Date
Natco Pharma will hold a board meeting on 13 November 2026 to consider unaudited quarterly results and an interim dividend. Trading window closed until 15 November 2026.
Natco Pharma Capital Structure Change
Natco Pharma's ₹1,279.4 Crore rights issue closed on October 22, 2026. Shares were priced at ₹750 each on a ₹2 face value.
- Value
- ₹1,279 Cr
Other business update announcements
All →Italian Edibles Business Update
Italian Edibles revised its project timeline again, pushing commercial production from January 2027 to April 2027. Construction delays stem from steel prices, supply chain disruption, weather and labour shortages.
- Execution
- Commercial production revised to April 2027 from January 2027
Bajaj Finserv Business Update
Bajaj Finserv disclosed October 2026 monthly premium and new business data for its unlisted insurance subsidiaries. The figures are provisional.
Bajaj Finance Business Update
Bajaj Finance submitted its Half Yearly Report for FY2026-27 covering the six months to 30 September 2026. The report shows 28% consolidated PAT growth to ₹12,447 crore and a planned ₹17,500 crore capital raise.
Cohance Lifesciences Business Update
Cohance Lifesciences disclosed that USFDA issued the Establishment Inspection Report for its Pashamylaram facility, classifying the inspection as Voluntary Action Indicated. The inspection is now concluded.
Religare Enterprises Business Update
Religare Finvest, a material subsidiary, resumed lending after RBI lifted its Corrective Action Plan. It disbursed its first Loan Against Property on 6 November 2026.
Purple Wave Infocom Business Update
Purple Wave signed a 5-year data integration agreement with BPCL for its Hygiair devices. The Rs 10 crore figure is indicative, not firm order value.
- Execution
- 5 years